Loop Dx











The Problem

Sepsis is a life-threatening illness caused by the immune system's response to an infection.

- Responsible for 27 M of hospital admissions and 8 M deaths / year.
- During the first 3 h of inpatient, <40% of the sepsis patients have started the antibiotic therapy, increasing 10% the mortality rate / hour without treatment.
- · After 15 h, only 30-60% of blood cultures (for the identification of bacteria and fungi) are positive (poor sensitivity).

The Solution

Identify blood infection faster than 3 h in sepsis suspected patients in order to reduce their mortality (starting early the therapy)


- · Decrease mortality and morbidity
- · Decrease lenght of hospital stay
- Decrease antibiotic budget
- Decrease antibiotic resistance

The Product

SeptiLoop is a diagnostic device that analyze the biological activity of blood immune cells identifying a previous contact with a bacterial stimulus.

It is able to quantify directly from whole blood specific markers from the patient's own immune system - the "host response".

- Early detection (results in <3 h)
- Easy to use
- Room temperature storage



Founded

Proof of Concept

25 Septic suspected patients (2017) 50 Inflammatory related patients (2018-2019)

Business model validation

Patent Protection

Product Manufacturing

Clinical validation

CE Mark/Market Launch

€ 50-100 Disposable devices € 1000 D-Health Prototype **Budget**

€ 15,000 EIT Health Business Model Validation

€ 100-300 Price competitors

\$ 396.6 M (CAGR 9.1%)

Global sepsis diagnostic market in 2018

21-32% Potential Penetration Rate

1.16 M people/year (EU and USA Potential Market)

Europe 2.4 M units/year

USA 1.6 M units/year

Spain 50 k units/year

- € 350,000 Market validation and assay
- € 4-6 M Clinical validation, regulatory approval and comercialization



- 5% Market Valid.
- 45% Clinical Valid.
- 20% Regulation
- 30% Commercial.

The Team

CEO Enrique Hernández, PhD















COO

Erika Paola, MD, MSc











